2 news items
GlycoMimetics' Uproleselan Flunks In Late Stage Leukemia Study, Shares Sink
GLYC
6 May 24
.
The primary endpoint of the study was overall survival without censoring for transplant.
Secondary endpoints included incidence
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
GLYC
6 May 24
endpoints included incidence of severe oral mucositis, complete remission rate and remission rate. A total of 388 patients across 70 sites in nine
- Prev
- 1
- Next